CID4 has selected Ft. Collins, Colorado-based Veterinary Emerging Technologies Development Corporation (VetDC) to receive funding and management assistance. VetDC in-licenses, develops and commercializes technologies to address serious unmet medical needs in companion animals. 

In the first quarter of 2011, VetDC completed the acquisition of all North American veterinary rights to VDC-1101 (GS-9219) from Gilead Sciences, allowing for development and commercialization in animal cancer. VDC-1101 is an anti-proliferative agent that preferentially targets lymphoid cells and works by inhibiting DNA synthesis, leading to the induction of apoptosis or programmed cell death. In a recently completed animal study, VDC-1101 was well tolerated and demonstrated significant activity against spontaneous non-Hodgkin lymphoma in pet dog subjects (n=38). 

“We are extremely pleased to enter into this financing agreement with CID4,” said Steven Roy, President and Chief Executive Officer of VetDC. “The CID4 funding will not only help us advance our lead cancer program, but will also help increase employment to the company and the State of Colorado. Furthermore, CID4's solid reputation and deep industry connections have already proven valuable in helping VetDC raise additional capital.”